TERPS Trial for De Novo Oligometastic Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

October 18, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions
Prostate CancerOligometastatic Disease
Interventions
RADIATION

Prostate radiation (XRT)

Both arms will receive prostate radiation. Multiple treatment regimens are allowed per protocol.

DRUG

Systemic Therapy

All systemic therapy is provided as best prescribed for patient per their medical oncologist.

RADIATION

Stereotactic ablative radiation therapy (SABR)

SABR is delivered to those randomized to Arm 2.

Trial Locations (9)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

19107

RECRUITING

Sidney Kimmel Cancer Center at Jefferson Health, Philadelphia

21014

NOT_YET_RECRUITING

Upper Chesapeake Health, Bel Air

21044

RECRUITING

Central Maryland Radiation Oncology, Columbia

21061

RECRUITING

Baltimore Washington Medical Center, Glen Burnie

21201

RECRUITING

Maryland Proton Treatment Center, Baltimore

RECRUITING

UMMC, Baltimore

23114

RECRUITING

Bon Secours Cancer Institute at St. Francis, Midlothian

92093

RECRUITING

UC San Diego Moores Cancer Center, La Jolla

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER